E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
NF-kappaB activation stimulates transcription and replication of retrovirus XMRV in human B-lineage and prostate carcinoma cells.
Sakakibara, Shuhei, Sakakibara, Kaori, Tosato, Giovanna · Journal of virology · 2011 · DOI
Quick Summary
This study examined how inflammation in the body can affect a virus called XMRV. Researchers found that when inflammatory signals (like TNF-α) are activated in cells, they can turn up the volume on XMRV production. This suggests that conditions causing inflammation or certain viral infections might help XMRV spread in the body.
Why It Matters
Understanding how inflammation amplifies XMRV replication is critical for ME/CFS research, as it provides a potential mechanistic link between immune activation and viral persistence. If XMRV is causally involved in ME/CFS, this pathway could explain why inflammatory states and concurrent infections worsen symptoms in some patients.
Observed Findings
- TNF-α significantly augmented XMRV Gag protein production in infected cells.
- Two NF-κB binding sites (κB-1 and κB-2) were identified in the XMRV LTR U3 region, with p65/RelA binding confirmed at both sites.
- Only the κB-1 site mutation impaired responsiveness to TNF-α and EBV LMP1 in reporter assays.
- XMRV with κB-1 mutation replicated significantly less efficiently than wild-type virus across prostate carcinoma, HEK293, B-lymphoma, and EBV-immortalized cell lines.
Inferred Conclusions
- NF-κB activation directly enhances XMRV transcription and replication through the κB-1 binding site in the viral LTR.
- The κB-1 site is functionally essential for NF-κB-mediated viral amplification, while κB-2 plays a minor or non-essential role.
- Inflammatory cytokines, EBV infection, and other conditions triggering NF-κB activation may promote XMRV spread in human tissues.
Remaining Questions
- Does NF-κB-mediated XMRV amplification occur in primary human tissues or in vivo in infected individuals?
- Are ME/CFS patients with evidence of XMRV infection also showing elevated NF-κB activation compared to controls?
- Would therapeutic NF-κB inhibition reduce XMRV replication and improve outcomes in infected patients?
What This Study Does Not Prove
This in vitro cell study does not prove that XMRV causes ME/CFS or that inflammation-driven viral replication occurs in ME/CFS patients' bodies. The study also does not establish whether NF-κB activation is sufficient to cause disease or whether blocking this pathway would improve clinical outcomes. Correlation between NF-κB activation and XMRV levels in cells does not prove causation in living patients.
Tags
Biomarker:CytokinesGene Expression
Method Flag:No ControlsExploratory Only
Metadata
- DOI
- 10.1128/JVI.02333-10
- PMID
- 21270144
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →